For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide.

Phase 4

Recruiting

Conditions: Stroke
Brain Infarction
Cerebral Infarction
Brain Ischemia
Nervous System Diseases
Central Nervous System Diseases
Vascular Diseases

Brief Summary: This is a prospective, open, single-arm, the real world of clinical trials. The researchers plan to recruit 300 eligible patients. The main purpose of this study is to evaluate the effectiveness and safety of butylphthalide in the treatment of ischemic stroke, and to establish a population pharmacokinetic model of butylphthalide in elderly patients to explore its blood drug concentration. Correlation with its efficacy and adverse reactions.

Detailed Description: Ischemic stroke is one of the diseases that seriously threaten human health, with the characteristics of high incidence, high disability and high recurrence rate. Patients will not only suffer from impaired physical function, but also mental symptoms, social function and other obstacles, which seriously affect the quality of life.

Butylphthalide can improve the damage of central nervous system in patients with acute ischemic stroke, and can promote the improvement of patients with neurological deficits. Regarding the treatment of ischemic stroke with butylphthalide, there is still a lack of big data research based on real-world efficacy and safety; there is a lack of data on the pharmacokinetics of elderly patients and their correlation with adverse reactions.

Thus, it is estimated that 300 patients will be enrolled and given intravenous butylphthalide sodium chloride injection 25mg twice a day for 7-14 days, and then oral butylphthalide soft capsule 0.2g three times a day for 76-83 days. The patients will be collected for experiment before and after treatment. Laboratory data, electrocardiogram, NIHSS, mRS, combined medication and adverse events, etc., to evaluate the effectiveness and safety of butylphthalide in the treatment of ischemic stroke. In addition, a population pharmacokinetic model of butylphthalide in elderly patients was established for 50 of them.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

1.Head CT or MRI suggests the presence of intracranial hemorrhagic disease
2.Patients with cerebral embolism or suspected cerebral embolism with severe atrioventricular block disease, atrial fibrillation, myocardial infarction, heart valve disease, infective endocarditis, heart rate less than 50 beats per minute
3.Abnormal liver function (transaminase ALT or AST exceeding the upper limit of normal), abnormal renal function (creatinine exceeding the upper limit of normal), or suffering from other serious systemic diseases, etc
4.Allergy to Butylphthalide

Arm && Interventions

Group	Intervention	Description
A group of patients with ischemic stroke were treated with butylphthalide injection and capsules	Butylphthalide	Patients eligible for inclusion and exclusion are only divided into one group, no controls or other.

Primary Outcome Measures

Name	Time	Method
The incidence of adverse events caused by treatment	90 days	In a clinical trial, the probability of an unexpected and adverse medical event that occurs after a patient or clinical subject receives a trial drug, but it does not necessarily have a causal relationship with the treatment.

Secondary Outcome Measures

Name	Time	Method
NIHSS	90 days	NIH stroke scale (NIHSS) to assess the degree of neurological deficit in stroke patients. The score ranges from 0 to 42 points, the higher the score, the more severe the nerve damage. Patients with a baseline assessment of\> 16 points are likely to die, while those with a score of \<6 are likely to recover well; for each additional point, the probability of a good prognosis is reduced by 17%
mRS	90 days	Modified Rankin scale (mRS) is an indicator of the efficacy of functional disability. The score ranges from 0 to 5 points, and the clinical score will be increased to 6 points to indicate death. The higher the score, the more disability the patient is.
Correlation between blood drug concentration and adverse events	90 days	Try to find the relationship between pharmacokinetic parameters and adverse events

Locations (1): Shandong Provincial Qianfoshan Hospital
🇨🇳
Jinan, Shandong Provincial, China